Lung Cancer Treatment Trial
Phase 2
99
about 9.6 years
18+
38 sites in CA, CO, CT +15
What this study is about
This trial is testing different treatments for lung cancer. It includes drugs, surgery (resection), and radiation therapy (SBRT). The goal is to find the best treatment option based on specific characteristics of each patient's tumor.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Alectinib
- 2.Take Atezolizumab
- 3.Take Chemotherapy
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
alectinib, atezolizumab, cobimetinib, entrectinib, pralsetinib, vemurafenib
oral (Oral Capsule), injection (Injection), oral (Oral Tablet), oral
Primary: KRAS Cohort: Percentage of Participants With 3-5 Grade Adverse Events (AEs), KRAS Cohort: Percentage of Participants Without Delays of Surgery due to Treatment-related Adverse Events as Reported by the Investigator
Secondary: Circulating tumor DNA (ctDNA) Clearance Rate, Disease-free Survival (DFS), Event-free Survival (EFS), Investigator-assessed Response Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Overall Survival (OS), Percentage of Participants With Adverse Events (AEs)
surgery
Oncology